<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5DC6C56E-5498-45C1-A1BA-AA7261760404"><gtr:id>5DC6C56E-5498-45C1-A1BA-AA7261760404</gtr:id><gtr:name>Optofluidics Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C507BF58-0D64-49E0-A484-98F1D4890473"><gtr:id>C507BF58-0D64-49E0-A484-98F1D4890473</gtr:id><gtr:name>Photon Force Ltd</gtr:name><gtr:address><gtr:line1>34 , Melville Street</gtr:line1><gtr:city>Edinburgh</gtr:city><gtr:postCode>EH3 7HA</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/405AD0AF-01C2-4AF0-B5B6-C4F73FC62953"><gtr:id>405AD0AF-01C2-4AF0-B5B6-C4F73FC62953</gtr:id><gtr:name>INNODIA</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DC6C56E-5498-45C1-A1BA-AA7261760404"><gtr:id>5DC6C56E-5498-45C1-A1BA-AA7261760404</gtr:id><gtr:name>Optofluidics Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C507BF58-0D64-49E0-A484-98F1D4890473"><gtr:id>C507BF58-0D64-49E0-A484-98F1D4890473</gtr:id><gtr:name>Photon Force Ltd</gtr:name><gtr:address><gtr:line1>34 , Melville Street</gtr:line1><gtr:city>Edinburgh</gtr:city><gtr:postCode>EH3 7HA</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/405AD0AF-01C2-4AF0-B5B6-C4F73FC62953"><gtr:id>405AD0AF-01C2-4AF0-B5B6-C4F73FC62953</gtr:id><gtr:name>INNODIA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1A56C6D2-133A-481E-A6F6-FB543905ADAC"><gtr:id>1A56C6D2-133A-481E-A6F6-FB543905ADAC</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Peakman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM022927%2F1"><gtr:id>7F936945-C798-4A6E-863F-49512C0BE4FF</gtr:id><gtr:title>Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M022927/1</gtr:grantReference><gtr:abstractText>We propose to create a state-of-the-art facility for studying the function and nature of single human cells involved in disease processes, combining the latest developments in cell isolation and analysis of genes and proteins. The system will be developed in collaboration with industrial partners, and exemplified via cohesive research programmes in immune-mediated disease, regenerative medicine and cancer. These provide distinct challenges but have significant cross-talk, making them ideal for exploring the full potential of the facility. For example, cancer growth and spread are characterised by variants of cells from &amp;quot;self&amp;quot; developing ways of evading the immune system; whilst autoimmune and inflammatory disease (diabetes, arthritis) arises because the immune system targets self. Moreover, in transplantation and regenerative medicine, responses to self and neo-self cells are a major barrier to graft acceptance. Through the synergistic development of new technology platforms that analyse complex cellular processes in cancer, inflammation, autoimmunity and transplantation on a single site that houses all of the relevant expertise and related infrastructure already, we aim to resolve complex disease processes at the single cell level. The expertise and methodologies brought together by the consortium create an opportunity to share technological benefits in an overlapping set of systems. Our goal is that the Single Cell-Level Functional Proteomics and Genomics system, once developed, will accelerate clinically important discoveries about disease processes, their treatment and monitoring, and act as a model for the establishment of similar facilities in centres of excellence across a range of clinical arenas.</gtr:abstractText><gtr:technicalSummary>We propose to create a state-of-the-art facility for single cell functional analysis, combining the latest developments in cell sorting with microfluidics-based cellomics, optical proteomics and single cell expression and genomics analysis. The expertise and methodologies brought together by the consortium create an opportunity to share technological benefits in an overlapping set of systems. The approach is innovative in being highly enabling for research across multiple clinical arenas; we will be operative in relation to multiple source materials (tissue, blood, culture) and levels of abundance. We will exploit the power of mass cytometry (CyTOF already in place) to maximize pre-sort capability, with the bonus of higher purity and data focusing. The modular design presents a challenge in terms of ensuring that platforms can be linked; but offers the considerable advantage of not being locked into a single commercial technology platform that runs the risk of scientific and budgetary constraint. The strategy thus increases our research possibilities whilst reducing the overall risk. The system will be developed in collaboration with industry, and exemplified via cohesive research programmes in immune-mediated and infectious disease, regenerative medicine and cancer. These provide distinct challenges but have significant cross-talk, making them ideal for exploring the full potential of the facility. For example, cancer growth and dissemination are characterised by immune evasion and tolerance to self/neo-antigens, whereas autoimmunity is distinguished by failure of self-antigenic tolerance, and the transfer of heterologous and autologous cells in regenerative medicine can engender responses that oppose tolerance induction. Through the synergistic development of new technology platforms that analyse complex cellular processes in cancer, inflammation, autoimmunity and alloimmunity on one site, we aim to resolve complex disease processes at the single cell level.</gtr:technicalSummary><gtr:potentialImpactText>Potential beneficiaries, beyond the academic, include clinicians managing complex diseases and their patients; policy makers at national and international level; commercial entities.

Clinicians managing complex diseases and their patients, are expected to benefit from our discovery science, which offers the opportunity for new disease insights, biomarkers and therapeutic avenues. 

Policy makers and commercial entities will benefit from the success of our platform, should single cell analyses provide superior mechanistic, diagnostic and monitoring insights over conventional approaches, leading to shifts in technology development and deployment.

Acceleration of UK-based technology platforms such as these offers a competitive edge, leading to high-profile publications and international recognition, development of unique expertise, and knock-on effects on 3rd sector technologists based in the UK.

We would expect to see some or all of the above benefits emerging in a 3-7 year time-frame post-award.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2386712</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Photon Force Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of electronic sensors for fluorescence lifetime imaging (application to Quantic and on-going research).</gtr:description><gtr:id>390E29AB-89B2-4FB3-9B21-80F04E4C2229</gtr:id><gtr:impact>Development of electronic sensors for fluorescence lifetime imaging (application to Quantic and on-going research). Visiting Research Fellow (Jakub Nedbal), a full time Photon Force employee is based in the Ameer-Beg research group ~20% FTE.</gtr:impact><gtr:outcomeId>58c698c56c8fa4.27014710-1</gtr:outcomeId><gtr:partnerContribution>Development of electronic sensors for fluorescence lifetime imaging (application to Quantic and on-going research). Visiting Research Fellow (Jakub Nedbal), a full time Photon Force employee is based in the Ameer-Beg research group ~20% FTE.</gtr:partnerContribution><gtr:piContribution>Development of electronic sensors for fluorescence lifetime imaging (application to Quantic and on-going research). Visiting Research Fellow (Jakub Nedbal), a full time Photon Force employee is based in the Ameer-Beg research group ~20% FTE.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>INNODIA</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>INNODIA Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes H2020 EC - Innovative Medicines Initiative</gtr:description><gtr:id>02C3CEB0-DAD2-438B-A315-456ADB352B94</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>58c6519c70dce8.01813366-1</gtr:outcomeId><gtr:partnerContribution>Laboratory studies on biomarkers for T1D</gtr:partnerContribution><gtr:piContribution>one PhD student 
one Research assistant</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Optofluidics Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of microfluidic sensors for liquid biopsy</gtr:description><gtr:id>0393F702-2BC6-4740-91D1-30DBDCFB5816</gtr:id><gtr:impact>Development of microfluidic sensors for liquid biopsy.</gtr:impact><gtr:outcomeId>58c69758f04b94.04176926-1</gtr:outcomeId><gtr:partnerContribution>Development of microfluidic sensors for liquid biopsy.</gtr:partnerContribution><gtr:piContribution>Development of microfluidic sensors for liquid biopsy.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Frontiers in Bioimaging</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B221FF60-BD5C-4D95-A437-36EFF9620AB8</gtr:id><gtr:impact>14/7/2016 Ameer-Beg, S. M. (PI), &amp;quot;Imaging strategies for protein interaction monitoring in live cells&amp;quot;, Invited Speaker, Frontiers in Bioimaging 2016, London.</gtr:impact><gtr:outcomeId>58c69eb6a5fa94.92675209</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.imaging-git.com/events/frontiers-bioimaging-2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Colloquia, University of Dundee</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C4EC68E-F4B6-463C-B475-F1F7FEDD17F3</gtr:id><gtr:impact>6/11/2015 Ameer-Beg, S. M. (PI), &amp;quot;Advanced microscopy solutions for protein-protein interaction monitoring in live cells and organisms&amp;quot;, Invited Colloquia, University of Dundee, Division of Imaging and Technology in the School of Medicine.</gtr:impact><gtr:outcomeId>58c69fb017c9a6.89232142</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroscience Symposium, Kyoto, Japan</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29B07229-0AEA-4F9C-B1A8-804F5D789619</gtr:id><gtr:impact>16/3/2017 - Ameer-Beg, S. M. (PI), &amp;quot;Protein-protein interactions at the interface: Biophotonics approaches to live-cell dynamic FRET measurements&amp;quot;, Invited Speaker, UK-Japan Spring Neuroscience Symposium, Kyoto, Japan.</gtr:impact><gtr:outcomeId>58c69e388052b2.89620036</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.neuroscience2016.jnss.org/en/program.html</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK Multidisciplinary Project Award</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>73EF1E6F-CBF8-423B-A472-11098760DA7D</gtr:id><gtr:outcomeId>58c699fe058550.14215090</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>peptide immunotherapy for T1D.
Commercial collaboration with UCB
Funding from Wellcome trust</gtr:description><gtr:id>33E8F6A7-58B2-469A-B135-F23B5F5880A0</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>58c6a5a41953c6.42593039</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Therapeutic Intervention - Drug - Beta call multiple peptide immunotherapy Early clinical assessment</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.multipeptide.co.uk/about-multipept1de/</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of new advanced microscopy tools. Significant improvement in imaging throughput of fluorescence lifetime imaging and novel methods development. Key papers are in preparation.</gtr:description><gtr:id>5DE3D3F5-D08A-4C2B-BA31-FBC24D4D03FB</gtr:id><gtr:impact>Development of new advanced microscopy tools. Significant improvement in imaging throughput of fluorescence lifetime imaging and novel methods development. Key papers are in preparation.</gtr:impact><gtr:outcomeId>58c6a01e296e20.44588262</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of new advanced microscopy tools</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Multiplex single cell Gene expression for T lymphocytes</gtr:description><gtr:id>91BD64EE-30A2-48C7-821E-075CF6D3E63A</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>58c6566bb94b87.03557545</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Multiplex single cell Gene expression for T lymphocytes</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3591C99F-9577-4BC5-B6CE-C2F345353A35</gtr:id><gtr:title>New high-speed centre of mass method incorporating background subtraction for accurate determination of fluorescence lifetime.</gtr:title><gtr:parentPublicationTitle>Optics express</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9790944d747be3c385ed5522cbe0b869"><gtr:id>9790944d747be3c385ed5522cbe0b869</gtr:id><gtr:otherNames>Poland SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1094-4087</gtr:issn><gtr:outcomeId>58c695f9260a23.32302220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74C954A8-893F-4E02-82B5-F2DC61BC3835</gtr:id><gtr:title>Real-time fluorescence lifetime actuation for cell sorting using a CMOS SPAD silicon photomultiplier.</gtr:title><gtr:parentPublicationTitle>Optics letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4084de016337f6327040fd446abb6850"><gtr:id>4084de016337f6327040fd446abb6850</gtr:id><gtr:otherNames>Rocca FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0146-9592</gtr:issn><gtr:outcomeId>58c69635135ca7.10584633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F07916C4-F3F4-4817-B413-2402A6374B26</gtr:id><gtr:title>Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58b7fc80045948.33584610</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M022927/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>